Skip to main content
TipRanks
Go Ultimate75% OFF

Spineway SA (ALSPW) AI Stock Analysis

7 Followers
FR:ALSPW

Spineway SA

(Paris:ALSPW)

Select Model
Rating:50Neutral
Price Target:EUR 0.09â–¼(-4.26% Downside)
Action:reiterated
Date:10/17/26

The overall score of 50 reflects a company with a solid, low-debt balance sheet and improving operational metrics, offset by persistent unprofitability and a weak technical trend. The primary strength is financial stability, while the main risks are the inability to generate positive earnings and a stock price in a downtrend across all major moving averages.

Positive Factors
Revenue and Margin RecoverySteady multi-year revenue growth and a materially recovered gross margin indicate improving commercial traction and operating economics. If maintained, this progress can strengthen the company’s ability to scale its spinal implant platform and move closer to sustainable profitability over the next several quarters.
Negative Factors
Persistent Loss-Making OperationsDespite revenue and gross-margin improvement, Spineway has not yet converted its business into sustainable earnings. Persistent operating and net losses can consume capital, limit internally funded investment, and make future growth more dependent on continued financial support.

Spineway SA (ALSPW) vs. iShares MSCI France ETF (EWQ)

-50%-40%-30%-20%-10%0%10%20%FR:ALSPW-41.61%EWQ+1.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 3.36M
Dividend Yield
―
Average Volume (3M)
105.69K
Price to Earnings (P/E)
-1.4
Beta (1Y)
0.26
Revenue Growth
14.51%
EPS Growth
59.71%
Country
France
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Spineway SA Business Overview & Revenue Model

Company Description

Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion pro...

How the Company Makes Money

Spineway generates revenue primarily by selling spinal surgery products to healthcare providers and/or distributors, including spinal implants (devices implanted in the patient) and the associated surgical instruments and systems required to implant...

Spineway SA Financial Statement Overview

Summary

Revenue growth is strong at 11.5% and gross margins have recovered to 26.3%, but the company remains unprofitable with negative operating and net margins. The balance sheet is a key strength with a very low debt-to-equity ratio of 0.07, providing financial stability. Cash flow turned positive, a critical milestone, though free cash flow is neutral. Overall, the company is in a transition phase with improving fundamentals but no sustainable earnings yet.

Income Statement

45Neutral

Balance Sheet

75Positive

Cash Flow

50Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.42M12.43M11.95M10.52M7.43M4.29M
Gross Profit2.37M3.27M3.36M1.63M237.00K-1.45M
EBITDA-1.65M-1.12M-5.35M-4.79M-2.76M-1.04M
Net Income-2.36M-2.24M-3.86M-6.51M-3.14M-1.58M
Balance Sheet
Total Assets27.36M29.46M30.41M26.31M27.70M25.57M
Cash, Cash Equivalents and Short-Term Investments1.46M3.50M4.52M1.80M5.50M13.89M
Total Debt1.53M1.53M1.82M2.60M1.43M2.40M
Total Liabilities5.96M6.40M6.17M7.26M5.69M4.69M
Stockholders Equity21.40M23.06M24.24M19.05M22.00M20.88M
Cash Flow
Free Cash Flow00-3.27M-7.29M-13.89M-2.88M
Operating Cash Flow-1.57M424.00K-3.27M-5.83M-1.62M-1.79M
Investing Cash Flow-855.00K-1.17M-1.01M-1.39M-10.20M-578.00K
Financing Cash Flow-16.00K-269.00K7.01M3.49M3.72M11.45M

Spineway SA Technical Analysis

Technical Analysis SentimentNegative
Last Price0.09

Price Trends

50DMA0.10Negative
100DMA0.12Negative
200DMA0.13Negative

Market Momentum

MACD-0.00Negative
RSI46.14Neutral
STOCH30.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSPW, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.14 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALSPW.

Spineway SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALSPW against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:CVXFR:CVX52NeutralEUR 290.60M-7.18-120.57%―-100.00%-72.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALSPWFR:ALSPW50NeutralEUR 3.36M-1.42-10.63%―14.51%59.71%
FR:ALIMPFR:ALIMP41NeutralEUR 20.39M-4.70671.47%―24.35%15.00%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%FR:ALSPWFR:ALSAFFR:CVXFR:ALIMPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALSPW and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALSPWSpineway SA0.09-0.07-43.03%
FR:ALSAFSafe Orthopaedics0.64-1.76-73.33%
FR:CVXAffluent Medical SA4.673.09195.57%
FR:ALIMPImplanet SA0.14-0.07-32.50%

Spineway SA Corporate Events

Spineway Nine‑Month Revenue Slips as Supply Issues Hit Growth; Names Deputy CEO

Oct 15, 2026

Spineway reported nine‑month 2026 revenue of €8.0 million, down 7% year‑on‑year, with quarterly sales volatility driven by supply chain issues despite underlying demand. Q3 revenue fell 25% to €2.3 million, while France grew 4% and Asia surged 27% to...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 17, 2026